Taken together, these results suggest that the IL-33/ST2 axis may enhance the antitumor immunity by promoting the recruitment recruitment of type 1-polarized CD8+ T cells into tumor lesions in STS. The gene discussed is IL1RL1; the disease is neoplasm.